1344997-64-3

Upstream product

• 1373522-42-9 5-(3-(2-ethyl-3-(2-methoxyvinyl)phenyl)-1,2,4-thiadiazol-5-2-isobutyl)benzonitrile 
• 134604-07-2 2-bromo-5-nitrobenzonitrile 
• 1344997-63-2 5-(3-{2-ethyl-3-[(E)-2-(methyloxy)ethenyl]phenyl}-1,2,4-thiadiazol-5-yl)-2-(2-methylpropyl)benzonitrile 
• 1344997-62-1 5-(3-bromo-1,2,4-thiadiazol-5-yl)-2-isobutylbenzonitrile 
• 288251-96-7 2-(2-methylpropyl)-5-nitrobenzonitrile 
• 856167-68-5 2-(2-methylpropyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile 
• 856167-67-4 5-bromo-2-(2-methylpropyl)benzonitrile 
• 288251-97-8 5-amino-2-(2-methylpropyl)benzonitrile 

Downstream Products

• 1373522-37-2 5-(3-(2-ethyl-3-(2-(3-hydroxyazetidin-1-yl)ethyl)phenyl)-1,2,4-thiadiazol-5-yl)-2-isobutylbenzonitrile 
• 1373522-38-3 5-(3-(2-ethyl-3-(2-(piperidin-1-yl)ethyl)phenyl)-1,2,4-thiadiazol-5-yl)-2-isobutylbenzonitrile 

Relevant academic research and scientific papers

Discovery of novel 1,2,4-thiadiazole derivatives as potent, orally active agonists of sphingosine 1-phosphate receptor subtype 1 (S1P1)

A novel series of 1,2,4-thiadiazole compounds was discovered as selective S1P1 agonists. The extensive structure-activity relationship studies for these analogues were reported. Among them, 17g was identified to show high in vitro potency with reasonable free unbound fraction in plasma (Fu > 0.5%), good brain penetration (BBR > 0.5), and desirable pharmacokinetic properties in mouse and rat. Oral administration of 1 mg/kg 17g resulted in significant peripheral lymphocytes reduction at 4 h after dose and rapid lymphocytes recovery at 24 h. 17g showed a transient lymphopenia profile in the repeated dose study in mouse. In addition, 17g also demonstrated efficacy comparable to that of FTY720 (1) in the mouse EAE model of MS.

COMPOUNDS AS AGONISTS OF S1P1 RECEPTORS

Compounds of formula (I), processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases mediated by S1P1 receptors.